Catalyst Dossier · compiled by CeliA 🧫

H. Lundbeck A/S (HLUN-B.CO)

Pharmaceutical Preparations · market cap $6.0B · as of 2026-06-29

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

H. Lundbeck A/S (HLUN-B.CO) is a Danish CNS-focused pharmaceutical company with approximately 5,000 employees and a market cap of ~$6.04B. The company fields a broad pipeline spanning insomnia, depression, migraine, Alzheimer's disease, schizophrenia, alcohol dependence, stroke, and multiple system atrophy, with several assets at Phase 2–3 stages. No near-term catalysts are flagged in the calendar, and key financial metrics (cash, runway, dilution) are not provided in the available data.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Brexpiprazole	Phase 3	Sleep Disturbances
Lu AG13909	Phase 2	Cushing's Disease
Zicronapine	Phase 2	Schizophrenia
Azilect®	Phase 3	Parkinson's Disease
Gaboxadol	Phase 3	Primary Insomnia
Vortioxetine (Lu AA21004)	Phase 3	Major Depressive Disorder
Duloxetine	Phase 3	Major Depressive Disorder
Lu AG09222	Phase 2	Migraine
Idalopirdine	Phase 3	Alzheimer's Disease
Lu AE58054	Phase 2	Alzheimer's Disease
Olanzapine	Phase 3	Schizophrenia
Vortioxetine	Phase 2	Depressive Disorder
Eptinezumab	Phase 3	Migraine
Sertindole	Phase 3	Schizophrenia
Nalmefene	Phase 3	Alcohol Dependence
Desmoteplase	Phase 3	Stroke
Risperidone	Phase 3	Schizophrenia
Lu AF82422	Phase 2	Multiple System Atrophy

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for HLUN-B.CO (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 18 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.